Research Papers:
SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer
PDF | Full Text | How to cite
Metrics: PDF 2661 views | Full Text 3845 views
Anjie Zhu1, Peng Yuan1, Feng Du1, Ruoxi Hong2, Xiaoyan Ding3, Xiuqing Shi4, Ying Fan1, Jiayu Wang1, Yang Luo1, Fei Ma1, Pin Zhang1, Qing Li1, Binghe Xu1
1Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC), Beijing, China
2Department of Medical Oncology, Sun Yat-sen University Cancer center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China
3Department of Medical Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
4Department of Medical Oncology, Yuhuangding Hospital, Yantai, Shandong, China
Correspondence to:
Peng Yuan, email: [email protected]
Binghe Xu, email: [email protected]
Keywords: SPARC, osteonectin, triple-negative breast cancer, prognosis
Received: January 12, 2016 Accepted: May 02, 2016 Published: July 11, 2016
ABSTRACT
SPARC/osteonectin expression is reportedly altered in various malignancies. However, little is known regarding to the prognostic value of SPARC in triple-negative breast cancer (TNBC) patients. In this study, immunohistochemistry and immunoreactive scores (IRSs) were used to evaluate SPARC protein expression in primary tumors from 211 TNBC patients with up to 10 years of clinical follow-up data. High SPARC expression (IRS ≥3) was detected in 52.1% of primary tumors. Patients expressing high SPARC levels had worse disease-free survival (DFS) (HR=1.58, 95% CI: 1.01-2.47, P=0.044) and overall survival (OS) (HR=1.74, 95% CI: 1.06-2.85, P=0.029) than patients with lower SPARC levels. Furthermore, high SPARC expression was an independent prognostic factor for both DFS (HR=1.73, 95% CI: 1.10-2.73, P=0.018) and OS (HR=1.90, 95% CI: 1.14-3.16, P=0.014) in TNBC patients. These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer.